Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis
Posted inHematology-Oncology news

Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis

Bridging therapy before BCMA-directed CAR T-cell infusion in relapsed/refractory multiple myeloma impacts disease control and outcomes. This study analyzes regimen efficacy and safety in 399 patients, highlighting variable responses and safety profiles tied to disease burden and biological risk.
Ziftomenib Shows Clinically Meaningful Activity in Heavily Pretreated NPM1‑Mutated AML — A Targeted Option for a Molecularly Defined Relapse Population
Posted inHematology-Oncology news

Ziftomenib Shows Clinically Meaningful Activity in Heavily Pretreated NPM1‑Mutated AML — A Targeted Option for a Molecularly Defined Relapse Population

In the phase II registration cohort of KOMET‑001, oral menin inhibitor ziftomenib achieved a CR/CRh rate of 22% (61% MRD negativity) and an ORR of 33% in relapsed/refractory NPM1‑mutated AML with manageable toxicity, supporting further study and potential use as a molecularly targeted salvage option.